Chad Mirkin, PhD, and colleagues show that spherical nucleic acids can be used to regulate immune responses in a new study that could shift the way scientists think about developing therapeutic agents for many diseases.
Browsing: Clinical Breakthroughs
A new study shows that teenagers who had previously been heavy users of marijuana performed worse on long-term memory tests than those who never used cannabis, and they had abnormally shaped hippocampuses.
A new Northwestern Medicine study shows an experimental gene therapy may have promise for treating painful diabetic neuropathy.
In a recent review published in Nature Reviews Cardiology, Northwestern Medicine investigators outline strategies to reduce the rate of early postdischarge adverse events among patients with heart failure.
Many obstacles hinder vulnerable populations in the United States from seeking and receiving the healthcare they need. A series of studies by Northwestern Medicine investigator Melissa Simon shows that navigator programs can help patients get care despite barriers like income, insurance and language.
A new study by Northwestern Medicine and the University of Pennsylvania found that extending patch treatment beyond the standard eight-week duration is safe and leads to better smoking cessation rates.
A new Northwestern Medicine study published in the New England Journal of Medicine shows the drug Eylea is superior to other options for improving the eyesight of persons with poor vision due to diabetic macular edema, a major cause of diabetes-related vision loss.
A new Northwestern Medicine study provides evidence suggesting that high systolic blood pressure in younger adults increases their future cardiovascular disease risk.
A study from Northwestern Medicine and the American College of Surgeons suggests that penalizing hospitals for patient readmissions following surgery may be ineffective, and even counterproductive for improving the quality of hospital care in the United States.
A preliminary Northwestern Medicine study suggests that nonmyeloablative hematopoietic stem cell transplantation (HSCT) may reverse disability and improve quality of life for patients with relapsing-remitting multiple sclerosis (MS).